The number of FDA-approved precision oncology therapies has increased to nearly 100, yet less than 1 in 20 cancer patients receive these treatments.
Acurion is changing that.
Acurion's OncoGaze™ platform detects HRD.
HRD is the only clinically actionable genomic target shared across some of the deadliest human cancers.
OncoGaze™ workflow predicts clinically-actionable genomic biomarkers from routine digital histological tissue slides.
OncoGaze™ uncovers hidden morphological patterns invisible to the human eye – accelerating biomarker screening.
OncoGaze™ provides actionable genomic test results within seconds, rather than months, unlocking life-saving precision therapies when time matters most.
OncoGaze™ makes precision therapy relevant for more patients.
By delivering critical genomic insights at the biopsy stage, Acurion’s OncoGaze™ technology empowers oncologists to make precision therapy a reality for more patients.
This technology was developed by leading oncologists and some of the most highly cited cancer researchers in the world.
Let's bring precision oncology forward – together.
Explore how Acurion is driving immediate precision for optimal care.
Contact us for a demo of OncoGaze.